{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:27:43Z","timestamp":1778707663121,"version":"3.51.4"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1006\/gyno.2000.5902","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T18:50:18Z","timestamp":1032288618000},"page":"116-119","source":"Crossref","is-referenced-by-count":47,"title":["Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer"],"prefix":"10.1006","volume":"79","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.5902_RF1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5902_RF2","first-page":"8","article-title":"Long-term follow-up of GOG-111: a randomized trial comparing cisplatin combined with cyclophosphamide or paclitaxel in patients with stage III or IV epithelial ovarian cancer","volume":"9","author":"McGuire","year":"1999","journal-title":"Int J Gynecol Cancer"},{"key":"10.1006\/gyno.2000.5902_RF3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF4","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF6","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1006\/gyno.2000.5902_RF8","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF9","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","article-title":"Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study","volume":"13","author":"Francis","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5902_RF10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/gyno.1998.5065","article-title":"Phase 2 trial of single agent ifosfamide\/mesna in patients with platinum\/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent","volume":"70","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5902_RF11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/gyno.1998.5044","article-title":"Phase 2 trial of moderately high dose single agent mitoxantrone in platinum- and paclitaxel-refractory ovarian cancer","volume":"70","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5902_RF12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580095902X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580095902X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T20:57:47Z","timestamp":1557349067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580095902X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S009082580095902X"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.5902","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}